Literature DB >> 3977193

High risk of malignant melanoma in melanoma-prone families with dysplastic nevi.

M H Greene, W H Clark, M A Tucker, K H Kraemer, D E Elder, M C Fraser.   

Abstract

The risk of hereditary cutaneous malignant melanoma was evaluated in 401 members of 14 families with an autosomal dominant form of melanoma. We documented 127 primary melanomas in 69 family members, including 39 new melanomas diagnosed in 22 study participants from the time of first examination through a maximum of 8 years of follow-up. The 39 newly diagnosed melanomas occurred only in family members with dysplastic nevi, a known precursor of familial melanoma. Of 77 patients with dysplastic nevus syndrome without prior melanomas, 4 developed their first melanoma during prospective follow-up, as compared with 0.03 cases expected. The prospective age-adjusted incidence for melanoma was 14.3/1000 patients with dysplastic nevus per year, with a cumulative melanoma risk (+/- SE) of 7.2% (+/- 3.6) at 8 years. The actuarial probability of melanoma developing in family members with dysplastic nevi was 56.0% (+/- 10.1) from age 20 to age 59. This study confirms that dysplastic nevi are clinical markers of high risk for, and precursors of, hereditary melanoma.

Entities:  

Mesh:

Year:  1985        PMID: 3977193     DOI: 10.7326/0003-4819-102-4-458

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  31 in total

Review 1.  The detection and management of dysplastic nevi and early melanoma.

Authors:  J K Rivers
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

2.  Evidence for autosomal dominance and pleiotropy of the cutaneous malignant melanoma (CMM)/Dysplastic nevus (DN) gene.

Authors:  S J Bale; A Chakravarti
Journal:  Am J Hum Genet       Date:  1987-05       Impact factor: 11.025

3.  IL-23 Inhibits Melanoma Development by Augmenting DNA Repair and Modulating T Cell Subpopulations.

Authors:  Tahseen H Nasti; J Barry Cochran; Raj V Vachhani; Kristopher McKay; Yuko Tsuruta; Mohammad Athar; Laura Timares; Craig A Elmets
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

4.  A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.

Authors:  Kenneth G Linden; Sancy A Leachman; Jonathan S Zager; James G Jakowatz; Jaye L Viner; Christine E McLaren; Ronald J Barr; Philip M Carpenter; Wen-Pin Chen; Craig A Elmets; Joseph A Tangrea; Sung-Jig Lim; Alistair J Cochran; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-10

5.  Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity.

Authors:  A M Goldstein; N C Dracopoli; E C Ho; M C Fraser; K S Kearns; S J Bale; O W McBride; W H Clark; M A Tucker
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

6.  Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Authors:  Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

Review 7.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 8.  Early detection and prevention of cutaneous malignant melanoma: emphasis on Swedish activities.

Authors:  U Ringborg; B Lagerlöf; M Broberg; E Månsson-Brahme; A Platz; M Thörn
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

Review 9.  Malignant melanoma of the skin.

Authors:  B K Armstrong; C D Holman
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

10.  Identifying people at high risk of cutaneous malignant melanoma: results from a case-control study in Western Australia.

Authors:  D R English; B K Armstrong
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.